Current Oncology
Baseline and Dynamic Clinical–Laboratory Risk Models for Early Progression or Death During PD-(L)1 Blockade in Advanced NSCLC: Development and Internal Validation
By Mehmet Fatih Ozbay, Mehmet Hünür, Sertac Vurgun and 3 others.
Abstract
Background
We developed clinical–laboratory models for early progression or death within 90 days (EPD90) during PD-1/PD-L1 blockade in advanced non-small cell lung cancer. EPD90 is a pragmatic early-risk endpoint, not a diagnosis of hyperprogressive disease.